WASHINGTON, Aug. 14, 2018 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that
the U.S. Court of Appeals for the Federal Circuit denied petitions
for panel rehearing and rehearing en banc filed by West-Ward
Pharmaceuticals, a subsidiary of Hikma Pharmaceuticals, relating to
Vanda's U.S. Patent number 8,586,610 (the '610 Patent) for
Fanapt®. This denial by U.S. Court of Appeals for the Federal
Circuit leaves undisturbed its prior decision that West-Ward
Pharmaceuticals's Abbreviated New Drug Application for iloperidone
infringed the '610 Patent, and that West-Ward Pharmaceuticals had
not proven the '610 Patent invalid. The '610 Patent is set to
expire November 2, 2027.
About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the
development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of
patients. For more on Vanda Pharmaceuticals Inc., please
visit www.vandapharma.com.
About Fanapt®
For full U.S. Prescribing Information for Fanapt®, including
indication, Boxed Warnings and Important Safety Information, visit
our Web site at www.fanapt.com.
Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
View original
content:http://www.prnewswire.com/news-releases/vanda-wins-denial-of-petition-for-rehearing-on-fanapt-300697128.html
SOURCE Vanda Pharmaceuticals Inc.